Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Abstract Introduction Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide (AC) and non‐AC moderately emetogenic c...

Full description

Bibliographic Details
Main Authors:	Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	Cancer Medicine
Subjects:	aprepitant CINV NEPA netupitant palonosetron
Online Access:	https://doi.org/10.1002/cam4.6121

Similar Items

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
by: Jianhua Chang, et al.
Published: (2020-07-01)

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies
by: Winnie Yeo, et al.
Published: (2021-08-01)

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
by: Lee Schwartzberg, et al.
Published: (2019-05-01)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
by: Lorusso V
Published: (2016-06-01)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
by: Naohisa Yoshida, et al.
Published: (2019-01-01)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
by: Yi Cheng, et al.
Published: (2022-07-01)

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials
by: Yeo W, et al.
Published: (2024-04-01)

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
by: Jae Hwa Yoo, et al.
Published: (2018-12-01)

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects
by: Lorenzo Pradelli, et al.
Published: (2007-06-01)

Curative Effect of Aprepitant Preventing CINV
by: Shasha GUAN, et al.
Published: (2018-10-01)

Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy
by: Chan-Keng Yang, et al.
Published: (2016-02-01)

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
by: Koji Matsumoto, et al.
Published: (2020-05-01)

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
by: Luigi Celio, et al.
Published: (2022-08-01)

Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting
by: Li Quanfu, et al.
Published: (2018-03-01)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
by: Ai Gao, et al.
Published: (2023-07-01)

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
by: Aziz Eghbali, et al.
Published: (2023-07-01)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
by: Roberta Caputo, et al.
Published: (2020-03-01)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
by: Luigi Celio, et al.
Published: (2019-12-01)

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
by: Nicola Di Renzo, et al.
Published: (2020-01-01)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
by: Tingting Qiu, et al.
Published: (2021-08-01)

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
by: Alessandro Parisi, et al.
Published: (2022-08-01)

A study on the efficacy and safety of aprepitant injection in preventing and treating nausea and vomiting induced by platinum‐based chemotherapy in lung cancer
by: Yan Fei, et al.
Published: (2024-03-01)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
by: Chae Seong Lim, et al.
Published: (2013-03-01)

Clinician preference and comparison of the efficacy of ondansetron, granisetron, and palonosetron in preventing chemotherapy-induced nausea and vomiting among children receiving moderate or highly emetogenic chemotherapy
by: Rohan Bansal, et al.
Published: (2023-09-01)

Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation
by: Hang Zhang, et al.
Published: (2023-11-01)

CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING
by: I. A. Koroleva, et al.
Published: (2017-11-01)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
by: Rashad N, et al.
Published: (2017-03-01)

Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: A randomised clinical trial
by: Ingilala L Thanuja, et al.
Published: (2021-01-01)

Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan
by: Munenobu Kashiwa, et al.
Published: (2019-07-01)

Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer
by: I. A. Koroleva, et al.
Published: (2018-11-01)

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries
by: Marco Turini, et al.
Published: (2015-07-01)

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
by: Hamid Emami, et al.
Published: (2015-01-01)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
by: Shimokawa M, et al.
Published: (2022-09-01)

Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy
by: Raafat Abdel-Malek, et al.
Published: (2017-09-01)

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
by: Hisanori Shimizu, et al.
Published: (2018-12-01)

THE EFFICACY OF APREPITANT (NK-1 RECEPTOR ANTAGONIST) AS PROPHYLAXIS FOR POSTOPERATIVE NAUSEA AND VOMITING
by: Muhammad Akram, et al.
Published: (2020-04-01)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
by: Cindy Weinstein, et al.
Published: (2020-09-01)

Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
by: Soumya Simhadri, et al.

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
by: Yoshinori Wakasugi, et al.
Published: (2019-11-01)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
by: Semjon Willier, et al.
Published: (2019-11-01)